Is BDTX or EPRX more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Is BDTX or LRMR more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Larimar Therapeutics N/A -137.39% -97.65%

Does the media refer more to BDTX or LRMR?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 11 mentions for Larimar Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Larimar Therapeutics' score of 0.43 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BDTX or OCGN more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Ocugen N/A -127,987.80% -115.95%

Does the media favor BDTX or OCGN?

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 12 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Ocugen's score of -0.12 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XFOR or BDTX?

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 9 mentions for X4 Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat X4 Pharmaceuticals' score of 0.49 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Black Diamond Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PRTC or BDTX?

Black Diamond Therapeutics has a consensus target price of $9.83, indicating a potential upside of 397.89%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has better earnings & valuation, PRTC or BDTX?

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Black Diamond Therapeutics $70M 1.62 $22.37M -$0.75 N/A

Is PRTC or BDTX more profitable?

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Black Diamond Therapeutics N/A -32.10% -25.21%

Black Diamond Therapeutics (BDTX) Competitors

$1.98 +0.03 (+1.28%)

As of 11:17 AM Eastern

Compare

BDTX vs. EPRX, LRMR, OCGN, XFOR, and PRTC

Should you buy Black Diamond Therapeutics stock or one of its competitors? MarketBeat compares Black Diamond Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Black Diamond Therapeutics include Eupraxia Pharmaceuticals (EPRX), Larimar Therapeutics (LRMR), Ocugen (OCGN), X4 Pharmaceuticals (XFOR), and PureTech Health (PRTC). These companies are all part of the "biotechnology" industry.

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Black Diamond Therapeutics (NASDAQ:BDTX) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Black Diamond Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.62	$22.37M	-$0.75	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Black Diamond Therapeutics currently has a consensus price target of $9.83, suggesting a potential upside of 397.89%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 163.74%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Black Diamond Therapeutics had 9 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 3 mentions for Eupraxia Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Eupraxia Pharmaceuticals' score of 0.27 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -32.10% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Summary

Black Diamond Therapeutics beats Eupraxia Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Black Diamond Therapeutics has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Black Diamond Therapeutics currently has a consensus target price of $9.83, indicating a potential upside of 397.89%. Larimar Therapeutics has a consensus target price of $12.57, indicating a potential upside of 198.96%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Black Diamond Therapeutics has higher revenue and earnings than Larimar Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.62	$22.37M	-$0.75	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 11 mentions for Larimar Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Larimar Therapeutics' score of 0.43 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics' return on equity of -32.10% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Larimar Therapeutics	N/A	-137.39%	-97.65%

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Larimar Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Ocugen?

Black Diamond Therapeutics (NASDAQ:BDTX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Black Diamond Therapeutics' return on equity of -32.10% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Ocugen	N/A	-127,987.80%	-115.95%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Black Diamond Therapeutics presently has a consensus target price of $9.83, suggesting a potential upside of 397.89%. Ocugen has a consensus target price of $9.50, suggesting a potential upside of 639.30%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Black Diamond Therapeutics has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.62	$22.37M	-$0.75	N/A
Ocugen	$4.41M	98.81	-$67.85M	-$0.26	N/A

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 12 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Ocugen's score of -0.12 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Black Diamond Therapeutics beats Ocugen on 11 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Black Diamond Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Black Diamond Therapeutics' return on equity of -32.10% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

X4 Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

X4 Pharmaceuticals currently has a consensus price target of $9.70, suggesting a potential upside of 115.56%. Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 397.89%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Black Diamond Therapeutics has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	12.09	-$79.20M	-$1.20	N/A
Black Diamond Therapeutics	$70M	1.62	$22.37M	-$0.75	N/A

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 9 mentions for X4 Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat X4 Pharmaceuticals' score of 0.49 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Black Diamond Therapeutics beats X4 Pharmaceuticals on 15 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Black Diamond Therapeutics has a consensus target price of $9.83, indicating a potential upside of 397.89%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 12 more articles in the media than PureTech Health. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 0 mentions for PureTech Health. Black Diamond Therapeutics' average media sentiment score of 1.47 beat PureTech Health's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Black Diamond Therapeutics	Positive

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Black Diamond Therapeutics	$70M	1.62	$22.37M	-$0.75	N/A

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Summary

Black Diamond Therapeutics beats PureTech Health on 10 of the 13 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.46M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.63	9.06	269.91	24.87
Price / Sales	1.62	1,278.42	654.69	108.21
Price / Cash	3.70	44.95	28.89	37.44
Price / Book	1.00	17.97	11.40	6.45
Net Income	$22.37M	-$13.25M	$3.45B	$347.50M
7 Day Performance	13.83%	5.58%	3.66%	3.77%
1 Month Performance	3.40%	-1.60%	-0.49%	-0.40%
1 Year Performance	-17.71%	61.32%	77.51%	23.55%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	3.4224 of 5 stars	$1.98 +1.3%	$9.83 +397.9%	-18.8%	$113.46M	$70M	N/A	90	Positive News Earnings Report Analyst Revision
EPRX Eupraxia Pharmaceuticals	1.9344 of 5 stars	$6.72 +0.9%	$18.00 +167.8%	+28.7%	$437.00M	N/A	N/A	29	Upcoming Earnings Gap Up
LRMR Larimar Therapeutics	4.326 of 5 stars	$4.14 -1.5%	$12.57 +204.0%	+16.2%	$429.54M	N/A	N/A	30	Earnings Report Upcoming Earnings
OCGN Ocugen	2.0876 of 5 stars	$1.27 +2.0%	$9.50 +651.0%	+27.2%	$428.97M	$4.41M	N/A	80	Earnings Report Analyst Downgrade
XFOR X4 Pharmaceuticals	2.4444 of 5 stars	$4.52 +8.3%	$9.70 +114.7%	+211.4%	$424.91M	$35.11M	N/A	80	News Coverage Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. EPRX, LRMR, OCGN, XFOR, and PRTC

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Ocugen?

Summary

How does Black Diamond Therapeutics compare to X4 Pharmaceuticals?

Summary

How does Black Diamond Therapeutics compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. EPRX, LRMR, OCGN, XFOR, and PRTC

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Do insiders and institutionals hold more shares of BDTX or EPRX?

Which has preferable earnings & valuation, BDTX or EPRX?

Do analysts recommend BDTX or EPRX?

Does the media prefer BDTX or EPRX?

Which has more volatility & risk, BDTX or EPRX?

Is BDTX or EPRX more profitable?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Which has more volatility & risk, BDTX or LRMR?

Do analysts rate BDTX or LRMR?

Which has stronger valuation & earnings, BDTX or LRMR?

Does the media refer more to BDTX or LRMR?

Is BDTX or LRMR more profitable?

Do institutionals and insiders believe in BDTX or LRMR?

Summary

How does Black Diamond Therapeutics compare to Ocugen?

Is BDTX or OCGN more profitable?

Do institutionals & insiders hold more shares of BDTX or OCGN?

Do analysts prefer BDTX or OCGN?

Which has more volatility & risk, BDTX or OCGN?

Which has preferable valuation and earnings, BDTX or OCGN?

Does the media favor BDTX or OCGN?

Summary

How does Black Diamond Therapeutics compare to X4 Pharmaceuticals?

Is XFOR or BDTX more profitable?

Which has more volatility & risk, XFOR or BDTX?

Do analysts recommend XFOR or BDTX?

Which has better valuation & earnings, XFOR or BDTX?

Does the media refer more to XFOR or BDTX?

Do institutionals and insiders have more ownership in XFOR or BDTX?

Summary

How does Black Diamond Therapeutics compare to PureTech Health?

Do institutionals & insiders have more ownership in PRTC or BDTX?

Do analysts prefer PRTC or BDTX?

Which has more risk & volatility, PRTC or BDTX?

Does the media favor PRTC or BDTX?

Which has better earnings & valuation, PRTC or BDTX?

Is PRTC or BDTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools